Abstract |
The outcome of T cell acute lymphoblastic leukemia ( T-ALL) is poorly understood. Allogeneic hematopoietic stem cell transplantation (HSCT) remains 1 of the best options to cure T-ALL. However, many patients cannot find an HLA-matched donor. Our institute established a new protocol for haplo-identical HSCT. Busulfan, cyclophosphamide, cytosine arabinoside, and methyl CCNU plus antithymocyte globulin was used for conditioning therapy. Seventy-two patients diagnosed with T-ALL underwent transplantation from haploidentical donor family members. The incidence rates of grades II to IV acute graft-versus-host disease (aGVHD) and of grades III and IV aGVHD were 49% ± 12% and 19% ± 12%, respectively. The cumulative incidence rate for chronic GVHD (cGVHD) at 2 years after HSCT was 41% ± 12%. After a median follow-up of 12 months, 15 patients had relapsed, 14 died from relapse, and 41 patients were still alive without disease recurrence. The probability of leukemia-free survival (LFS) was 44.2% ± 7.4% at 3 years. Patients transplanted during their first complete remission (CR1) had a lower relapse rate (18.8% versus 37.5%, P = .049, with a relative risk [RR] = 0.247, P = .007), a lower nonrelapse mortality (NRM) rate (16.6% versus 50.0%, P = .046, with an RR = 0.279, P = .024), and better LFS (54.8% versus 12.5%, P = .001, with an RR = 0.315, P = .004) compared with patients transplanted beyond CR1. This study confirmed that haploidentical/mismatched HSCT could be an alternative treatment choice for T-ALL.
|
Authors | Yu Wang, Dai-Hong Liu, Lan-Ping Xu, Kai-Yan Liu, Huan Chen, Yu-Hong Chen, Wei Han, Xiao-Hui Zhang, Xiao-Jun Huang |
Journal | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
(Biol Blood Marrow Transplant)
Vol. 18
Issue 5
Pg. 716-21
(May 2012)
ISSN: 1523-6536 [Electronic] United States |
PMID | 21924223
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- HLA Antigens
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Child
- Child, Preschool
- Disease-Free Survival
- Female
- Follow-Up Studies
- Graft Survival
- Graft vs Host Disease
(prevention & control)
- HLA Antigens
(immunology)
- Haplotypes
(immunology)
- Hematopoietic Stem Cell Transplantation
(methods)
- Histocompatibility
- Humans
- Male
- Middle Aged
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
(immunology, mortality, therapy)
- Recurrence
- Severity of Illness Index
- Transplantation Conditioning
|